TNF and rheumatoid arthritis: RA patients receiving methotrexate and rituximab (an antibody targeting B-cells) or leflunomide (an immunosuppressant) presented fewer sites with bleeding on probing than those receiving methotrexate and TNFα inhibitor [47].